Patrys nabs NZ patent for cancer antibody
Patrys (ASX:PAB) has been granted a New Zealand patent for anticancer antibody candidate PAT-LM1.
The patent covers the use of the antibody or its functional fragments to bind to target gene protein Nmt55/NONO for the prevention and treatment of tumour metastasis.
The NONO protein is expressed on numerous types of cancer cells and has been shown to upgregulate tumour cell growth and metastases.
This marks the second jurisdiction after the US for which Patrys has secured a patent covering PAT-LM1.
“New Zealand is a major market in the Australasian region and it is very pleasing to add this patent to Patrys’ already extensive portfolio,” Patrys CEO Marie Roskrow said.
Patrys last year conducted a $2.85 million capital raising, partly to help take PAT-LM1 out of preclinical development and into the trial stage.
The company is also in clinical trials for another anticancer antibody - PAT-SM6 - in melanoma and in multiple myeloma.
Patrys shares were trading 6.9% higher at $0.031 as of around 1 pm on Friday.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
